Pub Date : 2017-11-09DOI: 10.24217/2530-4984.17V1S1.00003
L. D. García, A. R. Mariblanca, I. García, L. D. Soto, E. R. García, M. Moreno, Alberto M. Borobia Pérez
{"title":"Sospecha de NET por Alergical expectorante en ausencia de datos histológicos y microbiológicos.","authors":"L. D. García, A. R. Mariblanca, I. García, L. D. Soto, E. R. García, M. Moreno, Alberto M. Borobia Pérez","doi":"10.24217/2530-4984.17V1S1.00003","DOIUrl":"https://doi.org/10.24217/2530-4984.17V1S1.00003","url":null,"abstract":"","PeriodicalId":257309,"journal":{"name":"IBJ Clinical Pharmacology","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122057568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-11-09DOI: 10.24217/2530-4984.17V1S1.00005
R. Garcia, S. C. Molina, Alberto M. Borobia Pérez
{"title":"Hiperpigmentacion inducida por antihipertensivos.","authors":"R. Garcia, S. C. Molina, Alberto M. Borobia Pérez","doi":"10.24217/2530-4984.17V1S1.00005","DOIUrl":"https://doi.org/10.24217/2530-4984.17V1S1.00005","url":null,"abstract":"","PeriodicalId":257309,"journal":{"name":"IBJ Clinical Pharmacology","volume":"61 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130619530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-11-09DOI: 10.24217/2530-4984.17V1S1.00008
M. Sánchez-Jareño, T. Bellón, Ana Fiandor, M. Marques-Mejias, A. Entrala, Rosario Cabañas
Se define como sindrome de DRESS a una reaccion cutanea grave caracterizada por la aparicion de erupcion cutanea, adenopatias, fiebre, eosinofilia, leucocitosis y/o afectacion organica a las 2-6 semanas de iniciar tratamiento con un farmaco. 1,2 Con mayor frecuencia, los farmacos implicados son anticonvulsivantes, sulfamidas, alopurinol y antibioticos betalactamicos. En el caso de las sulfamidas, la incidencia de reacciones cutaneas en general es del orden de 3-5 casos de cada 100 personas expuestas. 3 Presentamos un caso de sindrome de DRESS durante tratamiento con Sulfadiazina/Pirimetamina con reactivacion posterior con Sulfametoxazol/Trimetoprim y exantema con Clindamicina asociada a Pirimetamina. Confirmada hipersensibilidad retardada a sulfadiazina, sulfametoxazol y Pirimetamina mediante TTL (test de transformacion linfocitaria).
{"title":"DRESS en paciente con toxoplasmosis y síndrome antisintetasa.","authors":"M. Sánchez-Jareño, T. Bellón, Ana Fiandor, M. Marques-Mejias, A. Entrala, Rosario Cabañas","doi":"10.24217/2530-4984.17V1S1.00008","DOIUrl":"https://doi.org/10.24217/2530-4984.17V1S1.00008","url":null,"abstract":"Se define como sindrome de DRESS a una reaccion cutanea grave caracterizada por la aparicion de erupcion cutanea, adenopatias, fiebre, eosinofilia, leucocitosis y/o afectacion organica a las 2-6 semanas de iniciar tratamiento con un farmaco. 1,2 Con mayor frecuencia, los farmacos implicados son anticonvulsivantes, sulfamidas, alopurinol y antibioticos betalactamicos. En el caso de las sulfamidas, la incidencia de reacciones cutaneas en general es del orden de 3-5 casos de cada 100 personas expuestas. 3 Presentamos un caso de sindrome de DRESS durante tratamiento con Sulfadiazina/Pirimetamina con reactivacion posterior con Sulfametoxazol/Trimetoprim y exantema con Clindamicina asociada a Pirimetamina. Confirmada hipersensibilidad retardada a sulfadiazina, sulfametoxazol y Pirimetamina mediante TTL (test de transformacion linfocitaria).","PeriodicalId":257309,"journal":{"name":"IBJ Clinical Pharmacology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129874176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-10-21DOI: 10.24217/2530-4984.17V1.00009
Álvarez-Román, R. Berrueco-Moreno, S. Bonanad-Boix, M. Canaro‐Hirnyk, F. García-Candel, M. López-Fernández, M. Mingot-Castellano, A. Moretó-Quintana, R. Núñez-Vázquez, M. J. Paloma-Mora, Á. Palomo-Bravo, M. Rodríguez-López, A. S. Ortiz, I. Soto-Ortega, V. Jiménez‐Yuste
The main objective of this prospective observational study is to describe the pharmacokinetic profile of pa- tients with hemophilia A in prophylaxis with Advate® in Spain using myPKFiT®.
{"title":"Pharmacokinetic characterization of the population with hemophilia A in Spain, using an online medical application based on a published population model and a Bayesian algorithm.","authors":"Álvarez-Román, R. Berrueco-Moreno, S. Bonanad-Boix, M. Canaro‐Hirnyk, F. García-Candel, M. López-Fernández, M. Mingot-Castellano, A. Moretó-Quintana, R. Núñez-Vázquez, M. J. Paloma-Mora, Á. Palomo-Bravo, M. Rodríguez-López, A. S. Ortiz, I. Soto-Ortega, V. Jiménez‐Yuste","doi":"10.24217/2530-4984.17V1.00009","DOIUrl":"https://doi.org/10.24217/2530-4984.17V1.00009","url":null,"abstract":"The main objective of this prospective observational study is to describe the pharmacokinetic profile of pa- tients with hemophilia A in prophylaxis with Advate® in Spain using myPKFiT®.","PeriodicalId":257309,"journal":{"name":"IBJ Clinical Pharmacology","volume":"136 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123136459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-10-21DOI: 10.24217/2530-4984.17V1.00010
A. R. Mariblanca, J. Parada, R. Zabala, L. Cavero, D. N. Rodríguez, L. Sanabria, E. R. García
La importancia de la informacion de seguridad en las fichas tecnicas: a proposito de un caso.
数据表中安全信息的重要性:关于一个案例。
{"title":"La importancia de la información de seguridad en las fichas técnicas: a propósito de un caso.","authors":"A. R. Mariblanca, J. Parada, R. Zabala, L. Cavero, D. N. Rodríguez, L. Sanabria, E. R. García","doi":"10.24217/2530-4984.17V1.00010","DOIUrl":"https://doi.org/10.24217/2530-4984.17V1.00010","url":null,"abstract":"La importancia de la informacion de seguridad en las fichas tecnicas: a proposito de un caso.","PeriodicalId":257309,"journal":{"name":"IBJ Clinical Pharmacology","volume":"50 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130047007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-08-15DOI: 10.24217/2530-4984.17V1.00008
A. Borobia
ABSTRACT Objective: To evaluate efficacy, safety, patient and investigators satisfaction, and cost of pain relief by time unit between methoxyflurane (a volatile anesthetic agent with known analgesic properties, non-opioid, self-administered using a hand-held inhalation device under trained supervision) and emergency analgesic standard of care treatment (SoC), over a period of 30 min from start of administration and time to first pain relief. Methods: InMEDIATE is a phase IIIb, randomized, open label, multicenter, parallel group trial. It will be conducted in 15 emergency hospital departments. A total of 310 patients, with moderate to severe pain secondary to trauma, will be randomized to receive either methoxyflurane or SoC. The primary end point of the study is the change in mean pain intensity as measured by a numeric rating scale from randomization to 3, 5, 10, 15 and 20 minutes after treatment administration (using mixed-effect model repeated measure) and time to first pain relief (survival analysis).Discussion: To the best of our knowledge, this is the first randomized trial of methoxyflurane vs active analgesic treatment to be carried out in Europe. The aim of the study is to evaluate the results in terms of efficacy and safety of methoxyflurane for the treatment of traumatic pain in Spanish emergency units (ambulances, emergency primary care, and emergency departments settings), in order to assess the incorporation of this drug into the emergency traumatic pain SoC.Trial Registration: EudraCT, 2017â€000338â€70Keywords: Methoxyflurane, Inhaled anesthetic, Sedation, Traumatic pain, Emergency units.
{"title":"PHASE IIIb, OPEN LABEL RANDOMISED CLINICAL TRIAL TO COMPARE PAIN RELIEF BETWEEN METHOXYFLURANE AND STANDARD OF CARE FOR TREATING PATIENTS WITH TRAUMA PAIN IN SPANISH EMERGENCY UNITS (InMEDIATE): STUDY PROTOCOL","authors":"A. Borobia","doi":"10.24217/2530-4984.17V1.00008","DOIUrl":"https://doi.org/10.24217/2530-4984.17V1.00008","url":null,"abstract":"ABSTRACT Objective: To evaluate efficacy, safety, patient and investigators satisfaction, and cost of pain relief by time unit between methoxyflurane (a volatile anesthetic agent with known analgesic properties, non-opioid, self-administered using a hand-held inhalation device under trained supervision) and emergency analgesic standard of care treatment (SoC), over a period of 30 min from start of administration and time to first pain relief. Methods: InMEDIATE is a phase IIIb, randomized, open label, multicenter, parallel group trial. It will be conducted in 15 emergency hospital departments. A total of 310 patients, with moderate to severe pain secondary to trauma, will be randomized to receive either methoxyflurane or SoC. The primary end point of the study is the change in mean pain intensity as measured by a numeric rating scale from randomization to 3, 5, 10, 15 and 20 minutes after treatment administration (using mixed-effect model repeated measure) and time to first pain relief (survival analysis).Discussion: To the best of our knowledge, this is the first randomized trial of methoxyflurane vs active analgesic treatment to be carried out in Europe. The aim of the study is to evaluate the results in terms of efficacy and safety of methoxyflurane for the treatment of traumatic pain in Spanish emergency units (ambulances, emergency primary care, and emergency departments settings), in order to assess the incorporation of this drug into the emergency traumatic pain SoC.Trial Registration: EudraCT, 2017â€000338â€70Keywords: Methoxyflurane, Inhaled anesthetic, Sedation, Traumatic pain, Emergency units.","PeriodicalId":257309,"journal":{"name":"IBJ Clinical Pharmacology","volume":"48 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131567257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-08-01DOI: 10.24217/2530-4984.17V1.00007
H. Tong, L. D. García, S. García, José Antonio Ruíz Domínguez, J. Sánchez, Pilar, Storch de Gracias, Aris Rivas, M. Muñoz, Rafael Hernández Zabala, I. García, A. Borobia, Pérez, A. C. Sansuán, José Carlos Martí nez Ávila, E. R. Garcia
Acute and chronic paracetamol overdose in paediatric population: Protocol of a prospective study of cohort to evaluate clinic factor and biomarkers to predict development of hepatotoxicity.
儿科人群急性和慢性扑热息痛过量:一项评估临床因素和生物标志物以预测肝毒性发展的前瞻性队列研究方案。
{"title":"Acute and chronic paracetamol overdose in paediatric population: Protocol of a prospective study of cohort to evaluate clinic factor and biomarkers to predict development of hepatotoxicity.","authors":"H. Tong, L. D. García, S. García, José Antonio Ruíz Domínguez, J. Sánchez, Pilar, Storch de Gracias, Aris Rivas, M. Muñoz, Rafael Hernández Zabala, I. García, A. Borobia, Pérez, A. C. Sansuán, José Carlos Martí nez Ávila, E. R. Garcia","doi":"10.24217/2530-4984.17V1.00007","DOIUrl":"https://doi.org/10.24217/2530-4984.17V1.00007","url":null,"abstract":"Acute and chronic paracetamol overdose in paediatric population: Protocol of a prospective study of cohort to evaluate clinic factor and biomarkers to predict development of hepatotoxicity.","PeriodicalId":257309,"journal":{"name":"IBJ Clinical Pharmacology","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117210109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-02-03DOI: 10.24217/2530-4984.17V1.00006
M. Fernández-Ruiz, E. González, E. Hernández, M. Praga
Sindrome nefrotico secundario a glomerulonefritis membranosa asociada al tratamiento con litio.
与锂治疗相关的膜性肾小球肾炎继发肾病综合征。
{"title":"Síndrome nefrótico secundario a glomerulonefritis membranosa asociada al tratamiento con litio.","authors":"M. Fernández-Ruiz, E. González, E. Hernández, M. Praga","doi":"10.24217/2530-4984.17V1.00006","DOIUrl":"https://doi.org/10.24217/2530-4984.17V1.00006","url":null,"abstract":"Sindrome nefrotico secundario a glomerulonefritis membranosa asociada al tratamiento con litio.","PeriodicalId":257309,"journal":{"name":"IBJ Clinical Pharmacology","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115280386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-16DOI: 10.24217/2530-4984.17V1.00005
I. Dapía, A. Tabakov, L. Roman, L. Díaz, P. Lajara, M. Melgosa, Á. A. Melgar, C. Fernández, A. Estellés, P. Lapunzina, A. Borobia, A. Carcas
Effect of the CYP3A5, CYP3A4, CYP3A7, ABCB1, POR and NR1I2 genes in the pharmacokinetics of tacrolimus in a pediatric cohort with stable serum concentrations after renal transplantation: study protocol.
{"title":"Effect of the CYP3A5, CYP3A4, CYP3A7, ABCB1, POR and NR1I2 genes in the pharmacokinetics of tacrolimus in a pediatric cohort with stable serum concentrations after renal transplantation: study protocol.","authors":"I. Dapía, A. Tabakov, L. Roman, L. Díaz, P. Lajara, M. Melgosa, Á. A. Melgar, C. Fernández, A. Estellés, P. Lapunzina, A. Borobia, A. Carcas","doi":"10.24217/2530-4984.17V1.00005","DOIUrl":"https://doi.org/10.24217/2530-4984.17V1.00005","url":null,"abstract":"Effect of the CYP3A5, CYP3A4, CYP3A7, ABCB1, POR and NR1I2 genes in the pharmacokinetics of tacrolimus in a pediatric cohort with stable serum concentrations after renal transplantation: study protocol.","PeriodicalId":257309,"journal":{"name":"IBJ Clinical Pharmacology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128657787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-11DOI: 10.24217/2530-4984.17V1.00004
Miriam Saiz-Rodríguez, Daniel R. Romero Palacián, F. Abad-Santos
Objetivo: Estudiar la prevalencia de las enfermedades infecciosas que son atendidas en el Servicio de Urgencias y que requieren ingreso hospitalario, asi como identificar los principales agentes causales de las mismas y describir el tratamiento y evolucion de los pacientes. Metodo : Estudio observacional retrospectivo que evalua todos los pacientes que requieren ingreso urgente en un hospital terciario durante el mes de Marzo de 2016. Se recogieron como variables: enfermedades concomitantes, agentes causales, cultivos realizados, resistencias antibioticas y tratamiento prescrito. Las infecciones se clasificaron en: urinarias, respiratorias, intraabdominales, infeccion de piel y partes blandas, neurologicas, y otras. Resultados: Ingresaron un total de 903 pacientes durante este periodo. De estos, se considero que el 36,2% podian tener una causa infecciosa. La edad media fue de 72,3 anos. La estancia media en el hospital fue 9,6 dias. Las infecciones predominantes fueron respiratorias (47,2%), urinarias (19%) e intraabdominales (18,1%). El 46,5% de las pruebas microbiologicas fueron positivas, siendo E. coli el principal agente causal (22,3%). Los perfiles de sensibilidad de los aislados fueron similares a los esperados, excepto para K. pneumoniae (50% resistente a fluoroquinolonas y amoxicilina-clavulanico). Los antibioticos predominantemente prescritos fueron β-lactamicos (51,2%) y fluoroquinolonas (25,1%). La mortalidad fue del 7,3%, siendo los factores de riesgo asociados la edad y presentar criterios de sepsis. Conclusiones: Las infecciones suponen un alto porcentaje de la atencion en el Servicio de Urgencias, ademas de ser una de las principales causas de ingreso hospitalario. La edad avanzada es uno de los principales factores de riesgo de mortalidad en estos pacientes. Palabras clave : Infeccion bacteriana. Servicio de Urgencias. Ingreso hospitalario. Antibioterapia. Evolucion hospitalaria.
{"title":"Infecciones como causa de ingreso urgente en adultos en un hospital terciario.","authors":"Miriam Saiz-Rodríguez, Daniel R. Romero Palacián, F. Abad-Santos","doi":"10.24217/2530-4984.17V1.00004","DOIUrl":"https://doi.org/10.24217/2530-4984.17V1.00004","url":null,"abstract":"Objetivo: Estudiar la prevalencia de las enfermedades infecciosas que son atendidas en el Servicio de Urgencias y que requieren ingreso hospitalario, asi como identificar los principales agentes causales de las mismas y describir el tratamiento y evolucion de los pacientes. Metodo : Estudio observacional retrospectivo que evalua todos los pacientes que requieren ingreso urgente en un hospital terciario durante el mes de Marzo de 2016. Se recogieron como variables: enfermedades concomitantes, agentes causales, cultivos realizados, resistencias antibioticas y tratamiento prescrito. Las infecciones se clasificaron en: urinarias, respiratorias, intraabdominales, infeccion de piel y partes blandas, neurologicas, y otras. Resultados: Ingresaron un total de 903 pacientes durante este periodo. De estos, se considero que el 36,2% podian tener una causa infecciosa. La edad media fue de 72,3 anos. La estancia media en el hospital fue 9,6 dias. Las infecciones predominantes fueron respiratorias (47,2%), urinarias (19%) e intraabdominales (18,1%). El 46,5% de las pruebas microbiologicas fueron positivas, siendo E. coli el principal agente causal (22,3%). Los perfiles de sensibilidad de los aislados fueron similares a los esperados, excepto para K. pneumoniae (50% resistente a fluoroquinolonas y amoxicilina-clavulanico). Los antibioticos predominantemente prescritos fueron β-lactamicos (51,2%) y fluoroquinolonas (25,1%). La mortalidad fue del 7,3%, siendo los factores de riesgo asociados la edad y presentar criterios de sepsis. Conclusiones: Las infecciones suponen un alto porcentaje de la atencion en el Servicio de Urgencias, ademas de ser una de las principales causas de ingreso hospitalario. La edad avanzada es uno de los principales factores de riesgo de mortalidad en estos pacientes. Palabras clave : Infeccion bacteriana. Servicio de Urgencias. Ingreso hospitalario. Antibioterapia. Evolucion hospitalaria.","PeriodicalId":257309,"journal":{"name":"IBJ Clinical Pharmacology","volume":"517 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116238697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：